Nivolumab in NSCLC: Indication of major added benefit for under 75-year-olds

November 19th, 2015 | Posted by admin in Uncategorized

Under 75-year-olds in good general condition survive notably longer / hint of non-quantifiable added benefit in older patients.
Source: Medical News Today

You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *